Key result
Platelet activation marks pre-eclampsia and supports antiplatelet prophylaxis in high-risk pregnancies.
Answers are grounded in this paper and cite their sources.
Pronounced hemostatic changes occur during pregnancy, and the balance shifts markedly in favor of hypercoagulability. Although primarily a result of a marked rise in the levels of several procoagulants and a fall in some natural anticoagulants, platelet activation also contributes to this prothrombotic tendency. Several studies have confirmed the accentuation of platelet activation in pre-eclampsia (P-EC), which remains an important obstetric complication affecting ~2 to 4% of pregnancies. Although there is still a long way to go, significant inroads have been made in the understanding of this enigmatic condition. Whereas the pathogenesis of P-EC is protean and involves a complex interplay of placental and maternal tissues, platelet activation is likely to contribute to several clinical features. Several techniques have been used to assess platelet activation in P-EC. Detection of aberrations of platelet function and activation appear to have predictive value for its diagnosis. The findings also lend support to the use of antiplatelet agents as prophylaxis in those women with a high risk of developing the condition.
No takes yet. Share an insight, caveat, or question.
Kazmi et al. (2011) conducted a review in Pre-eclampsia. Platelet function assessment and antiplatelet prophylaxis was evaluated. Platelet activation is accentuated in pre-eclampsia, and detecting platelet function aberrations offers diagnostic value and supports antiplatelet prophylaxis in high-risk women.
Synapse has enriched 10 related papers. Consider them for comparative context: